Investing.com - NeuBase Therapeutics (NASDAQ:NBSE) (NASDAQ: NBSE) reported first quarter EPS of $-0.275, better than the analyst estimate of $-0.277. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
NeuBase Therapeutics's stock price closed at $0,200. It is down -100% in the last 3 months and down -93.46% in the last 12 months.
See NeuBase Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, NeuBase Therapeutics's Financial Health score is " performance".
Check out NeuBase Therapeutics's recent earnings performance, and NeuBase Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar